More recently, a nanopore-based assay has been introduced for the rapid sequencing of six genes frequently mutated in AML (NPM1, FLT3, CEBPA, TP53, IDH1, and IDH2) [18]. This evidence concerns the gene CEBPA and acute myeloid leukemia.